Core Thesis - Alphatec Holdings, Inc. (ATEC) presents a bearish investment thesis due to structural headwinds and material downside risks over the next 12 months, particularly following its 4Q'25 results [3][6] Company Overview - ATEC is a medical technology company focused on surgical treatments for spinal disorders, operating both in the United States and internationally [3] Market Dynamics - The company's flagship Prone TransPsoas (PTP) approach to lumbar fusion only addresses a subset of the spinal surgery market, with approximately 19% of fusion-eligible patients unable to use PTP and another 25-33% for whom it is non-ideal [3] - A significant portion of the target population, particularly those with spinal stenosis or herniated discs, either do not require fusion or are better served with decompression procedures, reducing the effective total addressable market to roughly $6 billion, which is about 42% below bullish estimates [4] Regulatory Environment - Regulatory pressures, such as CMS's WISER AI-driven pre-authorization for outpatient fusions, further constrain volumes, especially as outpatient procedures have increased from 2% to 26% of the market [4] Competitive Landscape - Competitor products have achieved technological parity, with ATEC lagging in surgical robotics and overall device functionality, which undermines its previous competitive advantage and limits future case growth [5] - The newly launched Valence robot is considered less capable than offerings from competitors like Medtronic, Globus, and Vista, leading to expectations of slow adoption [5] Financial Outlook - Recent growth in ATEC's sales was largely driven by elevated sales commissions, which are now being normalized, suggesting potential sales rep churn in FY'26 that could threaten surgical volume and market share [5] - Valuation multiples are expected to compress as ATEC faces decelerating sales growth, pricing pressure, and shrinking market opportunities, with a base-case target price of $14.2 indicating approximately 33% downside from current levels [6] - The company is viewed as a high-conviction short with substantial downside potential relative to its current market price [6]